Omeros Corporation $OMER Stock Holdings Lowered by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. reduced its holdings in Omeros Corporation (NASDAQ:OMER) by 18.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,514 shares of the biopharmaceutical company’s stock after selling 19,024 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.15% of Omeros worth $703,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 7,388 shares in the last quarter. Harbour Investments Inc. raised its holdings in shares of Omeros by 51.9% in the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,149 shares in the last quarter. Sowell Financial Services LLC bought a new stake in shares of Omeros in the 1st quarter worth approximately $88,000. Trexquant Investment LP bought a new stake in shares of Omeros in the 1st quarter worth approximately $88,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Omeros during the first quarter valued at approximately $142,000. 48.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on OMER. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Wednesday, September 3rd. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Omeros in a report on Friday, June 27th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, August 15th. Finally, Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Friday, June 27th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Omeros Stock Performance

Omeros stock opened at $4.15 on Friday. The firm has a market cap of $282.45 million, a PE ratio of -1.97 and a beta of 2.37. The firm’s 50 day moving average price is $3.97 and its two-hundred day moving average price is $5.15. Omeros Corporation has a twelve month low of $2.95 and a twelve month high of $13.60.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million. Equities analysts anticipate that Omeros Corporation will post -3.09 EPS for the current fiscal year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.